LGND vs TFSL
LGND: Ligand Pharmaceuticals is a high-margin, infrastructure-light aggregator of biopharmaceutical royalty streams, providing diversified exposure to late-stage drug commercialization and development. TFSL: A longstanding Ohio-based savings and loan association focused on residential mortgage lending and personal retail banking services.
Side-by-side fundamentals
| Metric | LGND | TFSL | Edge |
|---|---|---|---|
| Price as of 2026-10-30 close | $322.75 | $16.43 | |
| Market cap | $6.5B | $4.6B | |
| P/E as of 2026-10-30 | 129.62 (earnings are mostly non-operating: 51% of trailing pre-tax income, to 2026-09-30) | 45.64 | |
| PEG as of 2026-10-30, 3-year EPS CAGR to FY2025 | n/a | 6.37 | |
| Net margin FY2025, SEC XBRL | +46.4% | n/a | |
| Operating margin FY2025, SEC XBRL | +15.3% | n/a | |
| ROE FY2025, SEC XBRL | +12.2% | +4.8% | LGND higher |
| ROA FY2025, SEC XBRL | +8.0% | +0.5% | LGND higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-09-30 | 1.17 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +60.4% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +11.0% | n/a | |
| Dividend yield as of 2026-09-02 | n/a | 7.79% | |
| Dividend streak (yrs) SEC XBRL | 1 | 12 | TFSL higher |
| Beta as of 2026-09-03 | 0.97 | 0.61 | |
| 1-year return as of 2026-10-30 close | +72.5% | +24.0% | LGND higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.